Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP +1.66%60 EBITDA Margin % is 52.57% as of Mar. 2026, which is 349% above its 10-year median of 11.70. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 961 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 93.44% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Elite Pharmaceuticals EBITDA Margin % Related Terms
Elite Pharmaceuticals EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ELTP vs EOLS, EBS, AQST: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals (ELTP) has a EBITDA Margin % of 52.57% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elite Pharmaceuticals and its competitors. This is 349% above median its historical median of 11.70. According to the industry distribution chart, Elite Pharmaceuticals ranks #63 out of 961 companies in the Drug Manufacturers industry, placing it in the top 6.6%.
Is Elite Pharmaceuticals' EBITDA Margin % too high?
Elite Pharmaceuticals' current EBITDA Margin % of 52.57% is 349% above median its 10-year median of 11.70. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Elite Pharmaceuticals' value of 52.57% is 322.2% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #63 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' EBITDA Margin % compare to EOLS and EBS?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #63 out of 961 companies for EBITDA Margin %. This places Elite Pharmaceuticals in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.45. Elite Pharmaceuticals' value of 52.57% is 322.2% above this benchmark. While the company's 10-year median is 11.70 vs. the industry median of 12.45, Elite Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current EBITDA Margin % of 52.57% is 322.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current EBITDA Margin % is 52.57%, which is 349% above median its own 10-year median of 11.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.38 — trading 33.5% below its estimated fair value. The current EBITDA Margin % is 52.57%, which is 349% above median its 10-year median of 11.70 and 322.2% above the Drug Manufacturers industry median of 12.45. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current EBITDA Margin % is 52.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.38 is trading 33.5% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
EBITDA Margin %: 52.57% (349% above median its 10-year median of 11.70)
GF Value™: $0.57 vs. price of $0.38 (33.5% below fair value)
Industry Position: 322.2% above the Drug Manufacturers median (#63 of 961)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
